Bioniche go forward strategy NOT explained Wussy...I just re read your post.
McRae stated in the B ville Intelligencer interview , and I'm paraphrasing ' that they knew 6 or 7 month ago' that the trial was not moving at the pace required to complete a P3. That tells me the train was soon to derail and everybody who should have been aware was of the same opinion. Barring an FDA allowed revision to the trial, the trial could only be perceived as dead in its current structure.
I think that it is fair to assume that Endo was of the same opinion in that May/June period. I would also assume that both Endo and BNC would have begun contingency planning for Urocidin at that time. Anyone who has run a business can sense when they are in trouble and you absolutely don't wait until the receiver shows up to make alternative plans for survival.
The NR of yesterday said virtually nothing, but it did indicate that they are working on a go forward strategy. Really? if they knew 6 or 7 months ago that the trial was in serious danger of completion, wouldn't you have something in place now, if not months prior to cancelling it? I was left with the impression that BNC found out about this just days before the rest of us and are now scrambling for plan B. Of course that makes no sense based on what McRae said in the interview. Surely they have something in place now.
I think that shareholders are owed a bit more than "we are exploring our options". As we trade down towards the all time lows for the stock, the asks of management are minimal, humourous almost. Maybe asking for some concrete guidance, some idea of measurable plan is just too much of this semi-crown corporation to divulge.